A preliminary study of association of cigarette smoking with risk of neuromyelitis optica spectrum disorder

被引:1
|
作者
Yang, Ting-Ting [1 ]
Yin, He [1 ]
Liu, Pen-Ju [1 ]
Niu, Tian-Tong [1 ]
Wang, Ze-Yi [1 ]
He, Yang [2 ]
Yuan, Peng [1 ]
Zhang, Wei-Wei [1 ]
Xu, Bao-Lei [1 ]
Liu, Guang-Zhi [1 ]
机构
[1] Capital Med Univ, Beijing Anzhen Hosp, Dept Neurol, Beijing, Peoples R China
[2] Peking Univ, Dept Neurol, Peoples Hosp, Beijing, Peoples R China
关键词
multiple sclerosis; neuromyelitis optica spectrum disorder; risk; smoking; MULTIPLE-SCLEROSIS; MARKER;
D O I
10.1097/MD.0000000000027234
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Various studies have revealed an association between cigarette smoking and increased risk for multiple sclerosis (MS). However, its role in neuromyelitis optica spectrum disorder (NMOSD) remains elusive. Therefore, in the present case-control study, we aimed to assess the association of active and passive cigarette smoking with the risk of MS and NMOSD. Thirty-six patients with NMOSD, 46 patients with MS, and 122 healthy individuals were included in this study. Standardized questionnaires and telephone interviews were used to collect information regarding the active and passive cigarette smoking behaviors of the patients and normal controls. The risk of MS was significantly higher among smokers than among nonsmokers (odds ratio = 2.166, 95% confidence interval: 1.109-4.170; P = .027). Further analysis of the risk between active and passive smokers, male smokers and nonsmokers showed no statistical difference. However, neither smokers nor active smokers had a greater or lower risk of NMOSD than their nonsmoking counterparts. Our preliminary study showed no significant association between cigarette smoking and the risk of NMOSD, strongly suggesting that, unlike MS, cigarette smoking might not confer NMOSD susceptibility, at least in the Northern Han Chinese population.
引用
收藏
页数:5
相关论文
共 50 条
  • [31] COVID-19 and the risk of neuromyelitis optica spectrum disorder: a Mendelian randomization study
    Sun, Dongren
    Du, Qin
    Wang, Rui
    Shi, Ziyan
    Chen, Hongxi
    Zhou, Hongyu
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [32] Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset
    Collongues, N.
    Marignier, R.
    Jacob, A.
    Leite, M. I.
    Sivas, A.
    Paul, F.
    Zephir, H.
    Akman-Demirs, G.
    Elsone, L.
    Jarius, S.
    Papeix, C.
    Mutch, K.
    Saips, S.
    Wildemann, B.
    Kitley, J.
    Karabudak, R.
    Aktas, O.
    Kuscu, D.
    Altintas, A.
    Palace, J.
    Confavreux, C.
    De Seze, J.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (08) : 1086 - 1094
  • [33] Environmental risk factors in neuromyelitis optica spectrum disorder: a case-control study
    Eskandarieh, Sharareh
    Nedjat, Saharnaz
    Abdollahpour, Ibrahim
    Azimi, Amir Reza
    Moghadasi, Abdorreza Naser
    Asgari, Nasrin
    Sahraian, Mohammad Ali
    ACTA NEUROLOGICA BELGICA, 2018, 118 (02) : 277 - 287
  • [34] Efficacy of dalfampridine in neuromyelitis optica spectrum disorder: A pilot study
    de Seze, Jerome
    Clerc, Christine
    Bereau, Matthieu
    Bourre, Bertrand
    Zephir, Helene
    Collongues, Nicolas
    Kremer, Laurent
    Vermersch, Patrick
    Bigaut, Kevin
    MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2024, 10 (01)
  • [35] Contribution of germline and somatic mutations to risk of neuromyelitis optica spectrum disorder
    Yata, Tomohiro
    Sato, Go
    Ogawa, Kotaro
    Naito, Tatsuhiko
    Sonehara, Kyuto
    Saiki, Ryunosuke
    Edahiro, Ryuya
    Namba, Shinichi
    Watanabe, Mitsuru
    Shirai, Yuya
    Yamamoto, Kenichi
    Namkoong, Ho
    Nakanishi, Tomoko
    Yamamoto, Yuji
    Hosokawa, Akiko
    Yamamoto, Mamoru
    Nakajima, Kimiko
    Nishikawa, Rika
    Tanaka, Hiroaki
    Nakayamada, Shingo
    Matsuda, Koichi
    Nishigori, Chikako
    Sano, Shigetoshi
    Kinoshita, Makoto
    Koike, Ryuji
    Kimura, Akinori
    Imoto, Seiya
    Miyano, Satoru
    Fukunaga, Koichi
    Mihara, Masahito
    Shimizu, Yuko
    Kawachi, Izumi
    Miyamoto, Katsuichi
    Tanaka, Yoshiya
    Kumanogoh, Atsushi
    Niino, Masaaki
    Nakatsuji, Yuji
    Ogawa, Seishi
    Matsushita, Takuya
    Kira, Jun-ichi
    Mochizuki, Hideki
    Isobe, Noriko
    Okuno, Tatsusada
    Okada, Yukinori
    CELL GENOMICS, 2025, 5 (03):
  • [36] Urosepsis Risk in Neuromyelitis Optica Spectrum Disorder Patients Administered Satralizumab
    Fujita, Rina
    Aratake, Yuriko
    Nakata, Kyoko
    Fujii, Chihiro
    Kondo, Takayuki
    INTERNAL MEDICINE, 2023, 62 (22) : 3317 - 3320
  • [37] Fall frequency and risk factors in patients with neuromyelitis optica spectrum disorder
    Barzegar, M.
    Mirmosayyeb, O.
    Azarbayejani, R.
    Brand, S.
    Afshari-Safavi, A.
    Shaygannejad, V.
    Bahmani, D. Sadeghi
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 459 - 460
  • [38] Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder
    Fung, Simon
    Shirley, Matt
    CNS DRUGS, 2023, 37 (04) : 363 - 370
  • [39] Inebilizumab for treatment of neuromyelitis optica spectrum disorder
    Tullman, Mark J.
    Zabeti, Aram
    Vuocolo, Scott
    Dinh, Quinn
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2021, 11 (05) : 341 - 352
  • [40] Satralizumab in the treatment of neuromyelitis optica spectrum disorder
    Duchow, Ankelien
    Bellmann-Strobl, Judith
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2021, 11 (01) : 49 - 59